IntriCon (NASDAQ:IIN) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of IntriCon (NASDAQ:IIN) from a sell rating to a hold rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “IntriCon designs, develops, engineers and manufactures microminiaturized medical and electronic products. The Company supplies microminiaturized components, systems and molded plastic parts, primarily to the hearing instrument manufacturing industry, as well as the computer, government, electronics, telecommunications and medical equipment industries. The Company has facilities in the United States, Asia and Europe. “

Several other brokerages have also recently weighed in on IIN. Stifel Nicolaus set a $36.00 price target on IntriCon and gave the company a buy rating in a research report on Friday, July 19th. B. Riley set a $36.00 target price on IntriCon and gave the stock a buy rating in a research report on Friday, July 19th. Finally, ValuEngine upgraded IntriCon from a hold rating to a buy rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $38.75.

Shares of NASDAQ IIN opened at $17.91 on Friday. The stock has a market capitalization of $156.48 million, a PE ratio of 27.98, a PEG ratio of 7.69 and a beta of 0.68. IntriCon has a fifty-two week low of $16.81 and a fifty-two week high of $76.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.23 and a current ratio of 3.13. The company has a fifty day moving average of $20.92.

A number of institutional investors have recently bought and sold shares of IIN. Emerald Mutual Fund Advisers Trust purchased a new position in IntriCon during the first quarter worth about $4,399,000. Marshall Wace LLP grew its position in IntriCon by 51.4% during the first quarter. Marshall Wace LLP now owns 244,688 shares of the technology company’s stock worth $6,137,000 after buying an additional 83,103 shares in the last quarter. Roubaix Capital LLC grew its position in IntriCon by 141.8% during the second quarter. Roubaix Capital LLC now owns 141,301 shares of the technology company’s stock worth $3,301,000 after buying an additional 82,867 shares in the last quarter. Gamco Investors INC. ET AL grew its position in IntriCon by 288.1% during the second quarter. Gamco Investors INC. ET AL now owns 93,919 shares of the technology company’s stock worth $2,194,000 after buying an additional 69,719 shares in the last quarter. Finally, Kennedy Capital Management Inc. purchased a new position in IntriCon during the first quarter worth about $1,697,000. Institutional investors and hedge funds own 72.43% of the company’s stock.

About IntriCon

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.

Read More: What is systematic risk?

Get a free copy of the Zacks research report on IntriCon (IIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BidaskClub Lowers The Carlyle Group  to Hold
BidaskClub Lowers The Carlyle Group to Hold
Central European Media Enterprises  Lifted to Strong-Buy at BidaskClub
Central European Media Enterprises Lifted to Strong-Buy at BidaskClub
Celgene  Upgraded at BidaskClub
Celgene Upgraded at BidaskClub
BidaskClub Lowers Cadence Design Systems  to Buy
BidaskClub Lowers Cadence Design Systems to Buy
Cabot Microelectronics  Downgraded by BidaskClub
Cabot Microelectronics Downgraded by BidaskClub
Kala Pharmaceuticals  Raised to Buy at Zacks Investment Research
Kala Pharmaceuticals Raised to Buy at Zacks Investment Research


© 2006-2019 Ticker Report